Pharmacokinetics of drugs in cachectic patients: A systematic review

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Trobec, Katja ^a   Kos, Mojca Kerec ^b   Von Haehling, Stephan ^c   Springer, Jochen ^c,d   Anker, Stefan D ^e   Lainscak, Mitja ^a,c  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DIDANOSINE; EPIRUBICIN; FENTANYL; FLUOROURACIL; GANCICLOVIR; LAMIVUDINE; MATUZUMAB; METHOTREXATE; NEVIRAPINE; OXYCODONE; RIFABUTIN; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; CACHEXIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME MECHANISM; HUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; URINARY EXCRETION; DOSE CALCULATION; METABOLISM; PHARMACOKINETICS; TISSUE DISTRIBUTION;

BODY COMPOSITION; CACHEXIA; DRUG DOSAGE CALCULATIONS; HUMANS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84892516555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079603     Document Type: Article

References (61)

1. Marzo A (1997) Clinical pharmacokinetic registration file for NDA and ANDA procedures. Pharmacol Res 36: 425-450. doi:10.1006/phrs.1997.0254. PubMed: 9446710.
2. Chien JY, Ho RJ (2011) Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharmacol Sci 100: 53-58. doi:10.1002/jps.22253. PubMed: 20589750.
3. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V et al. (2008) Cachexia: a new definition. Clin Nutr 27: 793-799. doi:10.1016/j.clnu.2008.06. 013. PubMed: 18718696.
4. Baracos VE (2011) Pitfalls in defining and quantifying cachexia. J Cachexia Sarcopenia Muscle 2: 71-73. doi:10.1007/s13539-011-0031-9. PubMed: 21766051.
5. Seelaender MC, Nascimento CM, Curi R, Williams JF (1996) Studies on the lipid metabolism of Walker 256 tumour-bearing rats during the development of cancer cachexia. Biochem Mol Biol Int 39: 1037-1047. PubMed: 8866022.
6. Durham WJ, Dillon EL, Sheffield-Moore M (2009) Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care 12: 72-77. doi:10.1097/MCO.0b013e32831cef61. PubMed: 19057191.
7. Caldwell J, Gardner I, Swales N (1995) An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol 23: 102-114. doi: 10.1177/019262339502300202. PubMed: 7569663.
8. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W64 doi: 10.7326/0003-4819-151-4-200908180-00135. PubMed: 19622511.
9. Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y et al. (2012) Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol 68: 1411-1418. doi:10.1007/s00228-012-1266-x. PubMed: 22441315.
10. Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E et al. (2009) Transdermal fentanyl in cachectic cancer patients. Pain 144: 218-222. doi:10.1016/j.pain.2009.04.012. PubMed: 19442446.
11. Herrington JD, Tran HT, Riggs MW (2006) Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Cancer Chemother Pharmacol 57: 241-247. doi:10.1007/s00280-005-0012-9. PubMed: 16133538.
12. Gatti G, Di Biagio A, De Pascalis CR, Guerra M, Bassetti M et al. (1999) Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. Br J Clin Pharmacol 48: 704-711. PubMed: 10594472.
13. Pollock L, Else L, Poerksen G, Molyneux E, Moons P et al. (2009) Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. J Antimicrob Chemother 64: 1251-1259. doi:10.1093/jac/dkp358. PubMed: 19812065.
14. Mouly S, Aymard G, Tillement JP, Caulin C, Bergmann JF et al. (2001) Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome-a population pharmacokinetic study. Br J Clin Pharmacol 51: 557-565. doi:10.1046/j.0306-5251.2001.01389.x. PubMed: 11422015.
15. Mouly S, Aymard G, Diquet B, Caulin C, Bergmann JF (2000) Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. J Acquir Immune Defic Syndr 24: 344-351. doi:10.1097/00126334- 200008010-00008. PubMed: 11015151.
16. Trout H, Mentré F, Panhard X, Kodjo A, Escaut L et al. (2004) Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 48: 538-545. doi:10.1128/AAC.48.2.538-545.2004. PubMed: 14742207.
17. Brantley RK, Williams KR, Silva TM, Sistrom M, Thielman NM et al. (2003) AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum. Braz J Infect Dis 7: 16-22. PubMed: 12807688.
18. Gatti G, Papa P, Torre D, Andreoni M, Poggio A et al. (1998) Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 42: 2017-2023. PubMed: 9687400.
19. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ et al. (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67: 93-101. doi:10.1007/s00280-010-1288-y. PubMed: 20204364.
20. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54: 131-139. doi:10.1046/j.1365-2125.2002.01598.x. PubMed: 12207632.
21. Kumar RV, Gokhale SV, Ambaye RY, Shetty PA (1987) Pharmacokinetics of methotrexate in Indian children and its relationship to nutritional status. Chemotherapy 33: 234-239. doi: 10.1159/000238500. PubMed: 3608622.
22. Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C (2009) Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations. Clin Pharmacokinet 48: 477-487. doi: 10.2165/11313400-000000000-00000. PubMed: 19691369.
23. Knox C, Law V, Jewison T, Liu P, Ly S et al. (2011) DrugBank. p. 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39(Database issue): D1035-1041
24. UpToDate (2013)Basow DS, editor. Waltham, MA: UpToDate.
25. Liu W, Chen X, Ye Q, Hou S (2012) 3-hydroxycarboplatin, a simple carboplatin derivative endowed with an improved toxicological profile. Platinum Met Rev 56: 248. doi:10.1595/147106712X654204.
26. Marier JF, Dimarco M, Guilbaud R, Dodard C, Morelli G et al. (2007) Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J Clin Pharmacol 47: 1381-1389. doi:10.1177/0091270007307572. PubMed: 17962426.
27. (2011) Cymevene (ganciclovir powder for intravenous infusion): Data Sheet [online]. Roche Products Limited. Accessed 2013 Feb 01
28. (2012) Invirase (saquinavir mesylate capsules and tablets for oral use): Prescribing Information [online]; Genentech Inc. Accessed 2013 Feb 01.
29. (2011) Zerit stavudine hard capsule for oral use): Summary of Product Characteristics [online]. Bristol-Myers Squibb S.R.L. Accessed 2013 Feb 01
30. Jacques KA, Erstad BL (2010) Availability of information for dosing injectable medications in underweight or obese patients. Am J Health Syst Pharm 67: 1948-1950. doi:10.2146/ajhp100226. PubMed: 21048212.
31. von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 1: 1-5. doi:10.1007/s13539-010-0002-6. PubMed: 21475699.
32. Morley JE, Thomas DR, Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83: 735-743. PubMed: 16600922.
33. Murry DJ, Riva L, Poplack DG (1998) Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11: 48-51. PubMed: 9876478.
34. Oshikoya KA, Sammons HM, Choonara I (2010) A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol 66: 1025-1035. doi:10.1007/s00228-010-0851-0. PubMed: 20552179.
35. McLeay SC, Morrish GA, Kirkpatrick CM, Green B (2012) The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51: 319-330. doi: 10.2165/11598930-000000000-00000. PubMed: 22439649.
36. Barry RE (1974) Malignancy, weight loss, and the small intestinal mucosa. Gut 15: 562-570. doi:10.1136/gut.15.7.562. PubMed: 4430474.
37. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J et al. (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50: 1561-1569. doi:10.1016/j.jacc.2007.07.016. PubMed: 17936155.
38. Sandek A, Valentova M, von Haehling S, Doehner W, Anker SD (2011) The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol 146: 277-278. doi:10.1016/j.ijcard.2010.10.083. PubMed: 21112652.
39. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA (2008) Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 125: 240-245. doi:10.1016/j.ijcard.2007.11.103. PubMed: 18242735.
40. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M (1996) Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 25: 144-149. doi:10.1093/ageing/25.2.144. PubMed: 8670544.
41. Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356: 930-933. doi:10.1016/S0140-6736(00)02690-8. PubMed: 11036910.
42. Agustsson T, Wikrantz P, Rydén M, Brismar T, Isaksson B (2012) Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia. Nutrition 28: 851-855. doi:10.1016/j.nut.2011.11.026. PubMed: 22480800.
43. Fearon KCH, Preston T (1990) Body composition in cancer cachexia. Infusionstherapie 17: 63-66. PubMed: 2169464.
44. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J et al. (2012) Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status [Published online ahead of print Nov 22, 2012]. Endocrine. doi:10.1007/s12020-012-9836-3.
45. Pichard C, Kyle UG (1998) Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care 1: 357-361. doi: 10.1097/00075197- 199807000-00008. PubMed: 10565374.
46. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM et al. (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics.". Clin Nutr 29: 154-159. doi:10.1016/j.clnu.2009.12.004. PubMed: 20060626.
47. Nawaratne S, Brien JE, Seeman E, Fabiny R, Zalcberg J et al. (1998) Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 46: 447-452. PubMed: 9833597.
48. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26: 292-307. doi:10.2165/00003088-199426040-00005. PubMed: 8013162.
49. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S et al. (2010) The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 8: 85. PubMed: 20920199.
50. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P et al. (2011) Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol 146: 359-363. doi:10.1016/j.ijcard.2009.07.042. PubMed: 19703717.
51. Cederholm T, Wretlind B, Hellström K, Andersson B, Engström L et al. (1997) Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease. Am J Clin Nutr 65: 876-882. PubMed: 9062543.
52. Holroyde CP, Skutches CL, Boden G, Reichard GA (1984) Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 44: 5910-5913. PubMed: 6388829.
53. Edén E, Edström S, Bennegárd K, Lindmark L, Lundholm K (1985) Glycerol dynamics in weight-losing cancer patients. Surgery 97: 176-184. PubMed: 4038560.
54. Mulligan HD, Beck SA, Tisdale MJ (1992) Lipid metabolism in cancer cachexia. Br J Cancer 66: 57-61. doi:10.1038/bjc.1992.216. PubMed: 1637677.
55. Valentová M, von Haehling S, Doehner W, Murín J, Anker SD et al. (2012) Liver dysfunction and its nutritional implications in heart failure. [Published online ahead of print Sep 27, 2012] Nutrition doi:10.1016/j.nut.2012.06.002.
56. George J, Byth K, Farrell GC (1996) Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol 11: 33-39. doi:10.1111/j.1440-1746.1996.tb00007.x. PubMed: 8672739.
57. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36: 205-216. doi:10.1124/dmd.107. 018747. PubMed: 18218849.
58. Tepsuwan T, Schuarattanapong S, Woragidpoonpol S, Kulthawong S, Chaiyasri A et al. (2009) Incidence and impact of cardiac cachexia in valvular surgery. Asian Cardiovasc Thorac Ann 17: 617-621. doi: 10.1177/0218492309349093. PubMed: 20026539.
59. Trobec K, Knez L, Meško Brguljan P, Cufer T, Lainšč ak M (2012) Estimation of renal function in lung cancer patients. Lung Cancer 76: 397-402. doi:10.1016/j.lungcan.2011.11.016. PubMed: 22177534.
60. Patel SS, Molnar MZ, Tayek JA, Ix JH, Noori N et al. (2013) Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle 4: 19-29. doi:10.1007/s13539-012-0079-1. PubMed: 22777757.
61. the University Clinic of Pulmonary and Allergic Diseases (2000) Golnik Impact of Body Composition Changes and Cachexia on Bisoprolol and Ramipril Pharmacokinetics and Renal Function Estimation in Patients With Chronic Heart Failure. Available: Clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). - [cited 2013 Sep 2]. Available from: URL of the record NLM Identifier: NCT01829880.